Table 1.

randomized trials evaluating the prognosis/predictive impact of the mismatch repair status in stage II and III colorectal cancer

References	Tumor stage	Treatment	MMR status	Number of patients	HR for DFS/TTR/RFS (95% CI)	P value	HR for OS (95% CI)	P value
5-FU-based adjuvant chemotherapy
Sargent et al. (39) (pooled analysis)	II & III	Surgery alone 5-FU	pMMR	436 426	0.69 (0.55-0.86) DFS	0.001	0.73 (0.58-0.91)	0.006
		Surgery alone 5-FU	dMMR	79 86	1.61 (0.84-3.10) DFS	0.15	1.58 (0.81-3.09)	0.18
Sargent et al. (44) (from ACCENT)	II	Surgery alone	pMMR dMMR	244 63	0.27 (0.10-0.75) RFS	0.012	0.27 (0.10-0.74)	0.011
		5-FU	pMMR dMMR	920 235	0.81 (0.55-1.19) RFS	0.285	0.87 (0.61-1.26)	0.469
	III	Surgery alone	pMMR dMMR	277 37	0.59 (0.28-1.23) RFS	0.162	0.69 (0.35-1.36)	0.283
		5-FU	pMMR dMMR	2333 390	0.80 (0.66-0.97) RFS	0.025	0.79 (0.65-0.97)	0.023
Oxaliplatin-based adjuvant chemotherapy
Gavin et al. (54) (from the NSABP C-07 study)	II & III	5-FU 5-FU+oxaliplatin	pMMR	635 675	0.82 (0.67-1.00) TTR	0.054	NA
		5-FU 5-FU+oxaliplatin	dMMR	86 85	1.01 (0.45-2.25) TTR	0.98	NA
Gavin et al. (54) (from the NSABP C-07 and C-08 studies)	II & III	5-FU+oxaliplatin	pMMR dMMR	806 102	0.58 (0.35-0.96) TTR	0.03	NA
Flejou et al. (45) (from MOSAIC)	II & III	5-FU 5-FU+oxaliplatin	dMMR	50 40	0.52 (0.24-1.14) DFS	NA	0.45 (0.19-1.05)	NA
	III	5-FU 5-FU+oxaliplatin	dMMR	28 17	0.51 (0.18-1.41) DFS	NA	0.44 (0.15-1.34)	NA
Sinicrope et al. (67) (from N0147)	III	5-FU+oxaiplatin	pMMR dMMR	2575 329	0.82 (0.64-1.04) DFS	0.106	0.83 (0.63-1.09)	0.182
		5-FU+oxaiplatin	pMMR dMMR	2575 329	0.71 (0.55-0.93) TTR	0.014

DFS, disease free survival; RFS, recurrence free survival; TTR, time to recurrence; 5-FU, 5-fuluorouracil; HR, hazard ratio; CI, confidence interval; OS, overall survival; MMR, mismatch repair; pMMR, proficient MMR; dMMR, dMMR, deficient MMR; NA, not available